Ron Brookmeyer1, Nada Abdalla2, Claudia H Kawas3, María M Corrada4. 1. Department of Biostatistics, University of California, Los Angeles, CA, USA. Electronic address: rbrookmeyer@ucla.edu. 2. Department of Biostatistics, University of California, Los Angeles, CA, USA. 3. Department of Neurology, University of California, Irvine, CA, USA; Department of Neurobiology and Behavior, University of California, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA. 4. Department of Neurology, University of California, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA; Department of Epidemiology, University of California, Irvine, CA, USA.
Abstract
INTRODUCTION: We forecast the prevalence of preclinical and clinical Alzheimer's disease (AD) and evaluated potential impacts of primary and secondary preventions in the United States. METHODS: We used a multistate model incorporating biomarkers for preclinical AD with US population projections. RESULTS: Approximately 6.08 million Americans had either clinical AD or mild cognitive impairment due to AD in 2017 and that will grow to 15.0 million by 2060. In 2017, 46.7 million Americans had preclinical AD (amyloidosis, neurodegeneration, or both), although many may not progress to clinical disease during their lifetimes. Primary and secondary preventions have differential impact on future disease burden. DISCUSSION: Because large numbers of persons are living with preclinical AD, our results underscore the need for secondary preventions for persons with existing AD brain pathology who are likely to develop clinical disease during their lifetimes as well as primary preventions for persons without preclinical disease.
INTRODUCTION: We forecast the prevalence of preclinical and clinical Alzheimer's disease (AD) and evaluated potential impacts of primary and secondary preventions in the United States. METHODS: We used a multistate model incorporating biomarkers for preclinical AD with US population projections. RESULTS: Approximately 6.08 million Americans had either clinical AD or mild cognitive impairment due to AD in 2017 and that will grow to 15.0 million by 2060. In 2017, 46.7 million Americans had preclinical AD (amyloidosis, neurodegeneration, or both), although many may not progress to clinical disease during their lifetimes. Primary and secondary preventions have differential impact on future disease burden. DISCUSSION: Because large numbers of persons are living with preclinical AD, our results underscore the need for secondary preventions for persons with existing AD brain pathology who are likely to develop clinical disease during their lifetimes as well as primary preventions for persons without preclinical disease.
Authors: P J Neumann; S S Araki; A Arcelus; A Longo; G Papadopoulos; K S Kosik; K M Kuntz; A Bhattacharjya Journal: Neurology Date: 2001-09-25 Impact factor: 9.910
Authors: Ron Brookmeyer; Denis A Evans; Liesi Hebert; Kenneth M Langa; Steven G Heeringa; Brenda L Plassman; Walter A Kukull Journal: Alzheimers Dement Date: 2011-01 Impact factor: 21.566
Authors: Stephanie J B Vos; Frans Verhey; Lutz Frölich; Johannes Kornhuber; Jens Wiltfang; Wolfgang Maier; Oliver Peters; Eckart Rüther; Flavio Nobili; Silvia Morbelli; Giovanni B Frisoni; Alexander Drzezga; Mira Didic; Bart N M van Berckel; Andrew Simmons; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Cristina Muscio; Sanna-Kaisa Herukka; Eric Salmon; Christine Bastin; Anders Wallin; Arto Nordlund; Alexandre de Mendonça; Dina Silva; Isabel Santana; Raquel Lemos; Sebastiaan Engelborghs; Stefan Van der Mussele; Yvonne Freund-Levi; Åsa K Wallin; Harald Hampel; Wiesje van der Flier; Philip Scheltens; Pieter Jelle Visser Journal: Brain Date: 2015-02-17 Impact factor: 13.501
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Gwen Costa Jacobsohn; Matthew Hollander; Aaron P Beck; Andrea Gilmore-Bykovskyi; Nicole Werner; Manish N Shah Journal: J Am Geriatr Soc Date: 2019-01-09 Impact factor: 5.562
Authors: Lisa Vermunt; Sietske A M Sikkes; Ardo van den Hout; Ron Handels; Isabelle Bos; Wiesje M van der Flier; Silke Kern; Pierre-Jean Ousset; Paul Maruff; Ingmar Skoog; Frans R J Verhey; Yvonne Freund-Levi; Magda Tsolaki; Åsa K Wallin; Marcel Olde Rikkert; Hilkka Soininen; Luisa Spiru; Henrik Zetterberg; Kaj Blennow; Philip Scheltens; Graciela Muniz-Terrera; Pieter Jelle Visser Journal: Alzheimers Dement Date: 2019-06-01 Impact factor: 21.566
Authors: Tejus Pradeep; Michael J C Bray; Siddharth Arun; Lisa N Richey; Sahar Jahed; Barry R Bryant; Christian LoBue; Constantine G Lyketsos; Paul Kim; Matthew E Peters Journal: Int Rev Psychiatry Date: 2019-11-11
Authors: Kylie Ternes; Vijeth Iyengar; Helen Lavretsky; Walter D Dawson; Laura Booi; Agustin Ibanez; Ipsit Vahia; Charles Reynolds; Steven DeKosky; Jeffrey Cummings; Bruce Miller; Carla Perissinotto; Jeffrey Kaye; Harris A Eyre Journal: Int Psychogeriatr Date: 2020-02-13 Impact factor: 3.878